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Abstract
Catheter ablation is an established treatment option for symptomatic atrial fibrillation (AF), with circumferential pulmonary vein isolation 
being considered the cornerstone of the procedure. However, this is a complex intervention with potential major complications and with 
common arrhythmia recurrences. There is consensus among experts that all patients should be seen in follow-up regularly after AF ablation. 
To date there are limited data regarding the best methodology for routine clinical follow-up of this population. This review summarizes 
a contemporary insight into management of late complications following AF ablation, post-procedural anticoagulation and arrhythmia 
monitoring strategies, in order to prevent thromboembolic events, detect and treat arrhythmia recurrences, and discuss the use of upstream 
therapies after AF ablation. 
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Introduction
Catheter ablation is a standard treatment for patients with drug-
refractory symptomatic atrial fibrillation (AF), commonly performed 
throughout the world, that may provide long-term benefits regarding 
arrhythmia recurrence, complications and quality of life.1,2 The success 
of the procedure and the expanding training programs in this field 
have contributed to an increasing number of ablations performed 
worldwide. However, this is a complex intervention with potential 
major complications and with risk of arrhythmia recurrences. 
Therefore, there is consensus among experts that all patients should 
be seen in follow-up regularly after the ablation procedure. The best 
methodology for routine clinical care in order to recognize potential 
complications and optimize outcome results has not been fully 
elucidated yet. Nevertheless, a clinical follow-up protocol should 
include identification and management of late complications, a post-
procedural anticoagulation strategy, arrhythmia monitoring in order 
to detect and treat arrhythmia recurrences and control of associated 
comorbidities contributing to the risk of AF recurrence (figure 1).
What can we expect after AF ablation? Recovery from catheter 
ablation is usually quick (1-2 days). After removing the catheters, the 
patient lies flat for up to 6 hours to prevent bleeding from the puncture 
sites. Telemetry and blood pressure monitoring is recommended and 
the health team must be aware of symptoms, delayed complications 
and patient comorbidities. Common issues influencing the clinical 
outcome are the risk of thromboembolic events, early recurrence 
of atrial tachyarrhythmias and control of frequently associated 
comorbidities, like hypertension, diabetes, sleep apnea, or anxiety.
Late complications following AF ablation are inconsistently 
reported in retrospective surveys and include stroke, pericardial 
effusion and cardiac tamponade, iatrogenic atrial tachycardias, 
pulmonary vein (PV) stenosis, death (stroke, tamponade, atrio-
esophageal fistula), arteriovenous fistula and hematoma resulting 
from vascular access, and phrenic nerve injury1-3 (table I). A recent 
single-centre cohort analysis reported late complications in 4% of 
the patients submitted to AF ablation.4 Hopefully, improved ablation 
techniques and operator experience may contribute to the declining 
of complications rates.
The incidence of PV stenosis has varied substantially, depending 
on the ablative technique used and the method of assessment. 
Recent reports suggest that 1% to 10% of patients undergoing 
ablation develop PV stenosis.5,6 In the recent years, the incidence has 
fallen with improvements in the mapping and ablation techniques. 
Nevertheless, this problem continues to be reported and it accounts 
for approximately 30% of major complications.1-3
From a clinical point of view, some patients with mild (<50%) or 
moderate stenosis (50-70%) are asymptomatic.7 Symptoms caused 
by PV stenosis depend on the severity and the number of the affected 
veins and range from persistent cough, to chest pain, hemoptysis, and 
severe exertional dyspnea.
There is general agreement that patients with symptomatic severe 
PV stenosis should be treated with PV angioplasty with or without 
stenting. Treatment with catheter angioplasty can improve and, in 
some cases, completely relieve PV stenosis following AF ablation.8 
It has been shown that stent angioplasty is superior to balloon 
dilation in treating this complication.7,8 However, even with stent 
implantation, restenosis may occur in 30% to 50% of patients.8 Also, 
prompt referral for intervention and use of larger stents seem to be 
associated with lower restenosis rates and, therefore, with long-term 
patency.8
Post-procedural atrial tachycardias are relatively common and have 
been considered to be largely associated with circumferential ablation 
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observed on endoscopy following AF ablation has led to prophylactic 
use of proton pump inhibitors for one to four weeks after ablation 
in many centres. However, there are no data available available to 
demonstrate that this approach reduces the incidence of an atrio-
esophageal fistula. Therefore, current guidelines and consensus 
reports list no objectives on this issue.1
Phrenic nerve paralysis is another complication of AF ablation 
using cryoablation or radiofrequency energy, resulting from direct 
thermal injury to the right phrenic nerve. Although uncommon 
with radiofrequency energy (<1%), its incidence with the use of 
the cryoballoon system ranges from 4.7% to 11%, with a complete 
resolution noted in >80% of the cases.1,18,19
Follow-Up And Long-Term Management
Post-Procedural Anticoagulation
There is consistent evidence that a continuous warfarin strategy 
reduces periprocedural thromboembolic complications without 
increasing the risk of major bleeding events.20,21 Also, the use of 
dabigatran with the dose held on the day before the procedure and 
restarted immediately after AF ablation, seems to be safe and well 
tolerated, with no evidence of a higher risk of thromboembolic or 
bleeding complications compared to warfarin.22 Regarding the use of 
warfarin or new anticoagulants (direct thrombin inhibitors or factor 
Xa inhibitors), it has been recently suggested that both dabigatran 
and rivaroxaban are equally safe and effective when compared to 
warfarin.23
Low molecular weight heparin should be used 4-6h after sheat 
removal as a bridge to resumption of oral anticoagulation with 
warfarin or new anticoagulants.
There have been no large randomized prospective trials that have 
assessed the safety of stopping anticoagulation in this population. 
However, in most studies anticoagulation was continuously 
maintained for at least 3-6 months after ablation in patients 
who did not experience recurrent AF and had no incidents of 
thromboembolism. Current consensus recommends that decisions 
using wide-area circular lesions around the PV, or when additional 
ablation lines are incorporated in the procedure, creating an 
electrophysiologic milieu for both small and macroreentry circuits.9,10 
From a clinical point of view, these arrhythmias are characterized by: 
early onset of significant symptoms (frequent palpitations and fatigue) 
after ablation, refractory to management with rate-controlling drugs, 
limited amenability with antiarrhythmic drugs, and high recurrence 
rate after cardioversion.
Vascular access complications (hematoma, femoral pseudoaneurysm, 
arteriovenous fistula or retroperitoneal bleeding) are influenced by the 
number and size of sheats used, the need for anticoagulation before 
and after the procedure, and the operator experience. Incidence 
has been described in up to 13% of the cases1-3,11 and may require 
adequate manual compression or surgical repair.
The incidence of thromboembolism associated with AF ablation 
is reported to be between 0.9% and 7%.1-3,12 A thromboembolic 
phenomenon leading to stroke is a serious complication of AF 
ablation that typically occurs between 24 hours and the first 2 weeks 
after of the ablation procedure.13 In fact, a portion of the left atrium 
is burned during the procedure and the atria are often stunned after 
ablation. There is an increased risk of thromboembolism immediately 
following, and for several weeks after ablation, justifying optimal 
anticoagulation monitoring in order to achieve a safe level of 
thromboembolism prevention.
Cardiac tamponade is the most common life-threatening 
complication observed in patients undergoing AF ablation. The 
intense intraprocedural and post-procedural anticoagulation regimen 
recommended, together with extensive catheters manipulation, high 
levels of radiofrequency energy and the contact force exerted by the 
ablation catheter on the interface with cardiac tissue may expose 
patients to an excessive risk for bleeding. Delayed pericardial effusion 
(occurring >1h after ablation) leading to hypotension or cardiac 
shock is relatively rare in patients undergone a recent AF ablation.14,15 
However, attention should be given to chest pain, fatigue, dyspnea, 
tachycardia, and hypotension. Echocardiography confirms the 
diagnosis and pericardial drainage needs to be performed in most 
of the cases. Also, anticoagulation may be temporarily discontinued 
if the bleeding situation is maintained, and, in some cases, surgery is 
required in order to repair rupture of the atrial tissue.
A very rare, but potentially fatal, late complication is the atrio-
esophageal fistulae, formed from thermal injury from posterior wall 
of the left atrium causing damage of the esophagus. Although the 
incidence of the fistula is less than 1%, high mortality adds significance 
to the problem, making it one of the most feared complications of 
AF ablation.16,17 The observation that esophageal ulcerations may be 
Table 1: Clinical follow-up protocol after atrial fibrillation ablation
Transthoracic echo before discharge
outpatient clinic at 4 weeks and every 6 months thereafter
antiarrhythmics3-6 months;anticogulation 3-6 months
proton pump inhibitors for 1 week
patients with hypertension - ARB/ACEI
EKG (every regular appointment or if symptoms recurrence)
Event recorder or Implantable loop recorder
Holter recording 1st month and every 4 months
Table 2: CHA2DS2-VASc score and risk of stroke in atrial fibrillation
Risk factor Score
Congestive heart failure/LV dysfunction 1
Hypertension 1
Age≥75 2
Diabetes mellitus 1
Stroke/TIA/thrombo-embolism 2
Vascular diseasea 1
Age 65-74 1
Sex category (i.e. female sex) 1
Maximum score 9
Score CHA2DS2-VASc Annual risk of thromboembolic events (%/y)
0 0
1 1.3
2 2.2
3 3.2
4 4.0
5 6.7
6 9.8
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this event within the “blanking period” will not have any further 
arrhythmias.1,26 In our experience, the use of an external event loop 
recorder for the continuous detection of sudden arrhythmias during 
the first month after AF ablation documented sustained atrial 
tachyarrhythmias in 35,2% of the cases.27 However, the predictive 
positive value for the identification of patients with late arrhythmia 
recurrence was only 45%. Recently, in 630 patients who underwent 
circumferential pulmonary vein isolation and were implanted with 
a subcutaneous AF monitor it was suggested that the AF burden 
measured during the blanking period (with a calculated threshold of 
65.9 hours of AF during the first 2 months) can predict the response 
to catheter ablation at 12 months.28
The mechanisms of AF post-ablation may be different from that 
of the patient’s clinical arrhythmia and may resolve completely 
upon resolution of the inflammatory process. Therefore, is has been 
suggested to treat all patients with antiarrhythmic agents for the first 
3 months and delay re-ablation procedures for at least 3 months.1,26
Up to 35% of patients have recurrence of AF in the first year 
following catheter ablation. Multiple procedures may be considered 
to improve the long-term success of AF ablation. In a recent meta-
analysis, the overall average number of procedures was 1.51.25 Left 
atrial enlargement, pre-existing atrial fibrosis, type of AF, age, gender, 
hypertension, left ventricular dysfunction, and sleep apnea syndrome 
have been reported as independent predictors of success after 
single- or multiple-procedures.25,29-32 On an average, patients with 
nonparoxysmal AF are about 60% more likely to have AF recurrence 
after radiofrequency ablation than those with paroxysmal AF.30
Post-procedural atrial tachycardias have been considered to be 
associated with circumferential ablation using antral PV isolation 
and additional atrial ablation lines.33 Most of these tachycardias 
originate from reentry circuits in the left atrium and are responsible 
for complains of worsening symptoms. Rhythm control is usually 
difficult with antiarrhythmic drugs (AAD) and early recurrence 
is common after external cardioversion.9,10,33 Therefore, it often 
poses a more difficult clinical situation than the index arrhythmia. 
It has been proposed to maintain AAD therapy after electrical 
cardioversion and reserve a new ablation for patients in whom the 
arrhythmia did not disappear after a period of 3 months, because up 
to a third of these patients will present with resolution of their atrial 
tachycardia.33 The reablation procedure should obtain complete PV 
isolation and confirm bidirectional block of the previous lines. An 
activation mapping using tridimensional electroanatomic navigation 
systems is commonly complemented with detailed analysis of 
entrainment maneouvers to optimize the results of the procedure. 
Various authors have published promising results with these atrial 
tachycardias successfully ablated in 42% to 100% of the cases, but 
showing recurrence rates ranging from 21% to 44%.1,33
AAD are commonly used during the ﬁrst 3 months after AF 
ablation.1,34 The therapy most commonly employed for this purpose 
are the drugs that were unsuccessful prior to ablation. It has been 
suggested that its use restricted to this period reduces the need for 
hospitalization or cardioversion, without exposing the patient to 
serious side effects associated with their prolonged use.34
Should we maintain AAD or repeat PV isolation to prevent 
arrhythmia recurrences after AF ablation?
Pokushalov, et al, in a recent 154-patient study, compared those 
who underwent repeat PV isolation with patients taking AAD after 
recurrent paroxysmal AF. All patients received an implantable loop 
about continuation of oral anticoagulation with warfarin or newer 
anticoagulants thereafter should be based on the risk factors for 
stroke1 (figure 2). Among patients at high CHADS2Vasc score 
anticoagulation should be maintained life-long after the procedure 
even if the ablation appears to have eliminated AF.1,2 For patients with 
CHADS2Vasc ≤1, duration of anticoagulation has been suggested to 
be continued for at least 3 months.20
Arrhythmia Monitoring
Although catheter ablation significantly reduces the burden of AF, 
arrhythmia recurrences are common, both early and late following AF 
ablation, with a high proportion of asymptomatic episodes.24 Long-
term follow-up studies have shown that a single ablation procedure 
may be sufficient to achieve freedom from AF in 50% of patients, and 
that multiple procedures may control AF in 80% of patients.25
Arrhythmia monitoring to assess the efficacy of catheter ablation 
is typically delayed for 3 months. The use of this blanking period, 
during which transient tachyarrhythmia episodes are not considered 
recurrences, has been employed in studies examining the efficacy of 
radiofrequency catheter ablation of AF.  
Methods to evaluate arrhythmia recurrences during follow-up 
include: outpatient visits (ex. once in the first 3 months after ablation 
and every 6 months for 2 years), ECGs, 1-7 day Holter recording, 
telemedicine transmissions, and event loop recorders (non-invasive 
or implantable). A more intensive monitoring strategy is known to 
be associated with a greater likelihood of AF detection.
Although early recurrence of AF carries an independent risk of 
treatment failure, its occurrence should not prompt immediate 
re-ablation attempts, as about 50% of the patients experiencing 
Figure 1: An approach to a redo procedure after atrial fibrillation recurrence
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prospective studies are needed to conclusively answer that question.
There is some evidence suggesting that statins may have a role in 
the primary prevention of AF due to pleiotropic effects in relation 
with anti-inflamatory effects, improvement of endothelial function 
and antioxidant properties.39 In a meta-analysis performed to 
assess the potential benefits of statins on the recurrence of AF after 
electrical cardioversion or ablation, statins did not reduce the risk 
of AF occurrence following AF ablation (4 studies including 750 
patients).40 Thus, the role of statins post-AF ablation has not been 
established. Larger randomized controlled trials are required to 
further evaluate the role of statins after AF ablation.
Conclusion:
In conclusion, AF ablation have emerged as a successful 
therapeutic option. However, it is a complex procedure that is 
associated with potential major complications and with risk of 
arrhythmia recurrences.  Management of patients after hospital 
discharge requires commitment from the health team. Experience 
must be gained in the diagnosis and management of post-procedure 
complications (occurring in 3-7%), including delayed complications 
such as stroke, cardiac tamponade, esophageal injury, PV stenosis, 
and late hematoma/pseudoaneurysm or arteriovenous fistula.
Most of the authors maintain anticoagulation therapy  and AAD 
during the first 3-6 months after successful AF ablation. The risk-
benefit decision regarding the use of anticoagulation should be based 
on the actual risk scores. The role of ACEI/ARB after AF ablation 
stills controverse. The use of statins (without standard indications) 
is not recommended. Finnaly, the development of standard follow-
up programmes in order to prevent delayed complications and 
to optimize the success of catheter ablation reintervention may 
contribute to improve the long-term results of AF ablation.
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